Search results
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by King Luther Capital Management Corp
ETF DAILY NEWS· 14 hours agoKing Luther Capital Management Corp lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 4.6% in the fourth quarter, according to its most recent ...
Gilead Sciences Inc London Stock Price Today | NASDAQ 0QYQ Live Ticker - Investing.com
Investing.com· 3 hours agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Zacks via Yahoo Finance· 4 days agoGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you...
BMO maintains price target on Gilead stock amid oncology push By Investing.com
Investing.com· 2 days agoOn Thursday, BMO Capital Markets sustained its positive stance on Gilead Sciences (NASDAQ:GILD),...
Gilead (GILD) Announces Positive Interim Results on PBC Drug
Zacks via Yahoo Finance· 4 days agoGilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in...
PNC Financial Services Group Inc. Buys 4,745 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
ETF DAILY NEWS· 4 days agoPNC Financial Services Group Inc. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.3% during the fourth quarter, according to the company in ...
Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And...
Benzinga via Yahoo Finance· 4 days agoSaturday, Gilead Sciences Inc (NASDAQ:GILD), following the recent acquisition of CymaBay...
Positive trial outcomes lead BMO to maintain outperform rating on Gilead stock By Investing.com
Investing.com· 5 days agoOn Monday, BMO (TSX:BMO) Capital maintained its Outperform rating on Gilead Sciences (NASDAQ:GILD)...
Gilead's new liver disease med continues to deliver the goods ahead of FDA verdict
FierceBiotech· 5 days agoThree months after spending $4.3 billion on CymaBay Therapeutics for its primary biliary cholangitis...
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association...
Morningstar· 3 days agoGilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in ...